Shots:
- Health Canada has approved label expansion for Ixchiq against CHIKV disease in individuals (≥12yrs.)
- Approval was based on a P-III trial of Ixchiq vs PBO in adolescents over 6mos., which showed a superior high & sustained immune response in 99.1% of participants; data was published in The Lancet Infectious Diseases
- Additionally, label extension filing included antibody persistence data showing a sustained immune response in 97% of participants for 24mos., with durability consistent across younger & older adults
Ref: Valneva| Image: Valneva| Press Release
Related News:- Merck Receives Health Canada’s Approval for Perioperative Keytruda for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
